Complete Guide to Mycophenolate Pharmacokinetics
Overview
Mycophenolate is a Small Molecule used in the Transplant therapeutic area. It is indicated for Organ Transplant Rejection. Population PK simulator for mycophenolic acid (CellCept/Myfortic). Therapeutic drug monitoring with AUC targets.
Mechanism of Action
Mycophenolate exerts its pharmacological effect by targeting IMPDH. As a Small Molecule, it modulates this target to achieve therapeutic efficacy in Organ Transplant Rejection. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK models for Mycophenolate:
| Parameter | Value |
|---|---|
| Q | 35 L/h (intercompartmental CL) |
| CL | 33 L/h (typical, renal Tx) |
| V1 | 91 L (central volume) |
| V2 | 237 L (peripheral volume) |
| ka | 4.1 h⁻¹ |
| dose | 500-1500 mg BID (MMF) |
| lag time | 0.21 h |
| AUC target | 30-60 mg·h/L (renal Tx) |
| covariates | CrCL, albumin, ciclosporin dose, sex |
| CL covariate | CL = 33 × (CrCL/48)^(-0.12) × (Alb/30)^(-1.07) × (CSA/450)^0.31 × 1.11^sex |
| V1 covariate | V1 = 91 × (CrCL/48)^(-0.62) × (Alb/30)^(-1.13) |
| protein binding | 97% (albumin) |
| enterohepatic recirculation | yes |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Mycophenolate is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Transplant therapeutic area, for the treatment of Organ Transplant Rejection, understanding the pharmacokinetics of Mycophenolate is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Mycophenolate pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Mycophenolate PK Simulator
Explore Mycophenolate pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Mycophenolate?
The elimination half-life of Mycophenolate depends on patient-specific factors. Use our interactive Mycophenolate PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Mycophenolate administered?
Mycophenolate is administered via the Oral route. It is indicated for Organ Transplant Rejection. As a Small Molecule, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Mycophenolate?
Key pharmacokinetic parameters for Mycophenolate include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Mycophenolate dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Mycophenolate PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.